The "wagshurst study": P.Val40Ile transthyretin gene variant causes late-onset cardiomyopathy

Amyloid

Volumn 21, Issue 4, 2014, Pages 267-275

  Bauer, Ralf ^a   Dikow, Nicola ^b   Brauer, Andreas ^a   Kreuter, Michael ^b   Buss, Sebastian ^a   Evers, Christina ^b   Röcken, Christoph ^c   Schnabel, Philipp A ^a   Hinderhofer, Katrin ^b   Ehlermann, Philipp ^a   Katus, Hugo A ^a   Kristen, Arnt V ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Amyloidosis; Cardiomyopathy; Heart transplantation; Pulmonary amyloidosis; Transthyretin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; PREALBUMIN;

ARTERIAL WALL THICKNESS; ARTICLE; BLOOD LEVEL; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ASSESSMENT; DISEASE COURSE; DNA DETERMINATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FOLLOW UP; GENE MUTATION; GENETIC VARIABILITY; GERMANY; GROUPS BY AGE; HEART AMYLOIDOSIS; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE SEPTUM THICKNESS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LATE ONSET CARDIOMYOPATHY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MORTALITY; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PHENOTYPE; SCINTIGRAPHY; ADULT; AGED; COHORT ANALYSIS; FEMALE; GENETICS; MALE; MIDDLE AGED; ONSET AGE; PATHOPHYSIOLOGY; PEDIGREE;

ADULT; AGE OF ONSET; AGED; CARDIOMYOPATHIES; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEDIGREE; PREALBUMIN;

EID: 84908547427     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2014.967846     Document Type: Article

References (38)

1. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-62.
2. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referralAmyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011;97:75-84.
3. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-23.
4. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34: 520-8.
5. Shah PL, Gillmore JD, Copley SJ, Collins JV, Wells AU, du Bois RM, Hawkins PN, et al. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloid-osis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:134-42.
6. Roden AC, Aubry MC, Zhang K, Brady JO, Levin D, Dogan A, Yi ES. Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study. Hum Pathol 2010;41:1040-5.
7. Westermark P, Bergström J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopatholo-gic and structural considerations. Amyloid 2003;10:48-54.
8. Sack FU, Kristen A, Goldschmidt H, Schnabel PA, Dengler T, Koch A, Karck M. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg 2008;33:257-62.
9. Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 2013;106:528-40.
10. Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranløv PJ. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003;254:225-35.
11. Bittencourt PL, Couto CA, Clemente C, Farias AQ, Palácios SA, Mies S, Goldberg AC, et al. Phenotypic expression of familial amyloid polyneuropathy in Brazil. Eur J Neurol 2005;12:289-93.
12. Conceicao I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late-and early-onset cases in Portugal. Muscle Nerve 2007;35:116-18.
13. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
14. Rapezzi C, Longhi S, Milandri A, Lorenzini M, Gagliardi C, Gallelli I, Leone O, et al. Cardiac involvement in hereditary-transthyretin related amyloidosis. Amyloid 2012;19:16-21.
15. Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 2008;216:253-61.
16. Dwulet FE, Benson MD. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneur-opathy of Swedish origin. Proc Natl Acad Sci USA 1984;81:694-8.
17. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002;58:1001-7.
18. Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607-14.
19. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-73.
20. Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet 1990;47:127-36.
21. Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, Rowczenio D, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120-7.
22. Jacobson DR, Pan T, Kyle RA, Buxbaum JN. Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. Hum Mutat 1997;9:83-5.
23. Jenne DE, Denzel K, Blätzinger P, Winter P, Obermaier B, Linke RP, Altland K. A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis. Proc Natl Acad Sci USA 1996; 93:6302-7.
24. Altland K, Benson MD, Costello CE, Ferlini A, Hazenberg BP, Hund E, Kristen AV, et al. Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis 2007;28: 2053-64.
25. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, et al. Recommendation for chamber quantification: a report from the American society of echocardi-ography's guidelines and standards committee and left chamber quantification group, in conjunction with the European association of echocardiography. J Am Soc Echocardiogr 2005;18: 1440-63.
26. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiog-raphy. J Am Soc Echocardiogr 2009;22:107-33.
27. Puille M, Altland K, Linke RP, Steen-Muller MK, Kiett R, Steiner D, Bauer R. 99mTc DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002;29:376-9.
28. Lehrke S, Steen H, Kristen AV, Merten C, Lossnitzer D, Dengler TJ, Katus HA, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid 2009;16:187-95.
29. Chuang ML, Gona P, Salton CJ, Yeon SB, Kissinger KV, Blease SJ, Levy D, et al. Usefulness of the left ventricular myocardial contraction fraction in healthy men and women to predict cardiovascular morbidity and mortality. Am J Cardiol 2012;109: 1454-8.
30. Okamoto S, Hörnsten R, Obayashi K, Wijayatunga P, Suhr OB. Continuous development of arrhythmia is observed in Swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant). Liver Transpl 2011;17:122-8.
31. Reddi HV, Jenkins S, Theis J, Thomas BC, Connors LH, Van Rhee F, Highsmith Jr WE. Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life. J Mol Diagn 2014;16:68-74.
32. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;30:1008-10.
33. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-7.
34. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.
35. Kristen AV, Sack FU, Dösch A, Schnabel PA, Katus HA, Dengler TJ. The seven year itch? Promising long-term survival after heart transplant in a patient with transthyretin amyloidosis. Aktuel Kardiol 2012;1:286-9.
36. Koike H, Kiuchi T, Iijima M, Ueda M, Ando Y, Morozumi S, Tomita M, et al. Systemic but asymptomatic transthyretin amyl-oidosis 8 years after domino liver transplantation. J Neurol Neurosurg Psychiatr 2011;82:1287-90.
37. Ueda M, Ando Y, Haraoka K, Katsuragi S, Terasaki Y, Sugimoto M, Sun X, et al. Aging and transthyretin-related amyloidosis: pathologic examinations in pulmonary amyloidosis. Amyloid 2006;13:24-30.
38. Shah PL, Gillmore JD, Copley SJ, Collins JV, Wells AU, du Bois RM, Hawkins PN, et al. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloid-osis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:134-42.